Graig Suvannavejh
Stock Analyst at Mizuho
(4.21)
# 415
Out of 5,067 analysts
172
Total ratings
53.49%
Success rate
13.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Initiates: Neutral | $105 | $136.05 | -22.82% | 1 | Nov 20, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $82.11 | +21.79% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.60 | +116.98% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $74.00 | -24.32% | 7 | Nov 18, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $32 → $33 | $28.04 | +17.69% | 8 | Nov 13, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $34.66 | +32.72% | 3 | Nov 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $36 → $39 | $35.27 | +10.58% | 20 | Nov 6, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $200 → $202 | $151.20 | +33.60% | 22 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $24 → $19 | $20.13 | -5.61% | 11 | Nov 3, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $2 → $4 | $1.95 | +105.13% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.62 | +4,762.24% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $165 | $206.93 | -20.26% | 11 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.28 | +173.44% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.16 | +131.48% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $12 | $4.12 | +191.26% | 5 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $7.49 | +33.51% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $8.58 | +28.21% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $14.39 | +80.64% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.82 | -46.02% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $38.69 | -14.71% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.24 | +512.90% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $11.44 | +546.85% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $4.42 | +13.25% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $4.84 | -79.34% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $106.58 | -67.16% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $21.87 | -63.42% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $67.21 | -15.19% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $32.03 | -84.39% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.88 | +282.88% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $8.64 | +224.07% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $23.48 | +32.03% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $8.36 | +4,445.45% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.81 | +162.43% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $30.76 | +17.04% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $31.05 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.40 | +2,542.86% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $180.90 | -29.24% | 1 | Sep 14, 2020 |
Belite Bio
Nov 20, 2025
Initiates: Neutral
Price Target: $105
Current: $136.05
Upside: -22.82%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $82.11
Upside: +21.79%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.60
Upside: +116.98%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $74.00
Upside: -24.32%
Terns Pharmaceuticals
Nov 13, 2025
Maintains: Outperform
Price Target: $32 → $33
Current: $28.04
Upside: +17.69%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $34.66
Upside: +32.72%
Harmony Biosciences Holdings
Nov 6, 2025
Maintains: Outperform
Price Target: $36 → $39
Current: $35.27
Upside: +10.58%
Axsome Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $151.20
Upside: +33.60%
Apellis Pharmaceuticals
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $20.13
Upside: -5.61%
BioXcel Therapeutics
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.95
Upside: +105.13%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.62
Upside: +4,762.24%
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $206.93
Upside: -20.26%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.28
Upside: +173.44%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.16
Upside: +131.48%
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $4.12
Upside: +191.26%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $7.49
Upside: +33.51%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $8.58
Upside: +28.21%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $14.39
Upside: +80.64%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.82
Upside: -46.02%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $38.69
Upside: -14.71%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.24
Upside: +512.90%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $11.44
Upside: +546.85%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $4.42
Upside: +13.25%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $4.84
Upside: -79.34%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $106.58
Upside: -67.16%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $21.87
Upside: -63.42%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $67.21
Upside: -15.19%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $32.03
Upside: -84.39%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.88
Upside: +282.88%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $8.64
Upside: +224.07%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $23.48
Upside: +32.03%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $8.36
Upside: +4,445.45%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.81
Upside: +162.43%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $30.76
Upside: +17.04%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $31.05
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.40
Upside: +2,542.86%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $180.90
Upside: -29.24%